Drawray launched iStar 2000 Automatic CLIA Analyzer and Unicorn Series (FIA platform).

Drawray Medical Device Industrial Park has officially opened.

Drawray awarded "National High-tech Enterprise".

Drawray launched iStar 500 Automatic Monotest CLIA Analyzer.

Drawray's parent company YHLO launched IPO and listed on SSE STAR Market.

YHLO launched iFlash 1200, the smallest model of iFlash Family.

Drawray was established.

Awarded “Top Innovative Enterprises in Shenzhen".

Won the prize of "Innovation Star Cup for Excellent Reagent".

In 2018, Drawray Established. Drawray focuses on the research and development and innovation of POCT products in the field of in vitro diagnostics, attaches importance to the introduction and training of talents, and has established a multi-subjects and multi-layer elite team with entrepreneurial ideals . After that, the company awarded “Top Innovative Enterprises in Shenzhen”as well as won the prize of “Innovation Star Cup for Excellent Reagent”.

YHLO launched iFlash 1800(bench-top CLIA)and UNICELL POCT system.

Awarded“China Most Investment Valuable Brand in IVD Field".

Dr. Frank, the chief scientist of the company, awarded "Lifetime Honorary Award of China IVD Industry Leader".

YHLO awarded “National High-Tech Enterprise".

Launched iFlash 3000, China's first high throughput CLIA analyzer, and UNION, China's first monotest immunology analyzer.

Parent Company YHLO Biotech Established.  YHLO is an innovative and

steadfastly growing company of immunoassay solutions headquartered in

Shenzhen, China, specializes in developing, manufacturing and distributing in-

vitro diagnostic instruments and reagents by a team of experienced scientists and

engineers.